Ani Pharmaceuticals
ANI Pharmaceuticals Inc is an American specialty pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company operates through specialized manufacturing facilities in the United States, producing high-barrier generic drugs, anti-parasite medications, hormone products, and established branded pharmaceuticals across therapeutic categories including endocrinology, anti-infectives, and neurology. Its core business operations encompass pharmaceutical formulation development, contract manufacturing, regulatory compliance, and commercial drug distribution. Revenue is derived primarily from direct commercial sales of generic and branded prescription pharmaceuticals to wholesalers, pharmacies, and healthcare institutions. ANI Pharmaceuticals holds an established market position in niche generic pharmaceuticals and established brand treatments in North America. The company is headquartered in Baudette, Minnesota, United States, and its common stock trades on the Nasdaq Global Select Market.
6 of the funds FundTelligence covers report a position in Ani Pharmaceuticals.
- Legal name
- ANI PHARMACEUTICALS
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
Funds holding Ani Pharmaceuticals
- Aberdeen North American Smaller Companies Fund — Abrdn · 2.7 % (largest positions only, September 2026)
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.26 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- SEB Active 20 — SEB · 0.0 % (full portfolio disclosed, June 2026)